GLPG Stock Overview A biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Galapagos Historical stock prices Current Share Price €25.58 52 Week High €39.00 52 Week Low €22.00 Beta 0.038 1 Month Change 0.79% 3 Month Change -3.69% 1 Year Change -29.63% 3 Year Change -47.84% 5 Year Change -86.39% Change since IPO 59.88%
Recent News & Updates
Consensus EPS estimates upgraded to €0.90 loss Dec 04
Consensus EPS estimates fall from profit to €1.27 loss Nov 08
Forecast to breakeven in 2024 Nov 03
New minor risk - Profitability Nov 01 Galapagos NV to Report First Half, 2025 Results on Jul 23, 2025
Consensus EPS estimates increase by 185% Oct 23 See more updates
Consensus EPS estimates upgraded to €0.90 loss Dec 04
Consensus EPS estimates fall from profit to €1.27 loss Nov 08
Forecast to breakeven in 2024 Nov 03
New minor risk - Profitability Nov 01 Galapagos NV to Report First Half, 2025 Results on Jul 23, 2025
Consensus EPS estimates increase by 185% Oct 23
Consensus EPS estimates fall by 23% Oct 13
Galapagos NV Announces Board Changes Oct 07
Consensus EPS estimates fall by 49% Aug 28
Investor sentiment improves as stock rises 17% Aug 28
Galapagos Announces FDA Clearance of IND Application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in Relapsed/Refractory Non-Hodgkin Lymphoma Aug 24
Second quarter 2024 earnings released Aug 04
Galapagos NV to Report Fiscal Year 2024 Results on Feb 12, 2025 Aug 03
Consensus EPS estimates fall by 10% May 15
Consensus EPS estimates upgraded to €0.72 loss, revenue downgraded May 09
First quarter 2024 earnings released: EPS: €0.36 (vs €0.35 in 1Q 2023) May 04
Galapagos NV (AMS:GLPG) Analysts Are More Bearish Than They Used To Be Apr 19
Consensus revenue estimates decrease by 11% Apr 17
Full year 2023 earnings: EPS and revenues exceed analyst expectations Apr 01
Galapagos NV Announces Board Changes Mar 27
New major risk - Revenue and earnings growth Feb 23
Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024 Feb 16
Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV (ENXTAM:GLPG). Feb 01
Consensus EPS estimates fall by 14% Jan 30
Galapagos NV's (AMS:GLPG) Shares Lagging The Industry But So Is The Business Jan 03
Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos Jan 02
Galapagos Announces Start of PAPILIO-1 Phase 1/2 Multiple Myeloma Study of Point-Of-Care Manufactured BCMA CAR-T Candidate, GLPG5301 Dec 22
Galapagos Presents New Encouraging Clinical Data from the Ongoing Phase 1/2 CD19 CAR-T Studies with GLPG5201 and GLPG5101 Dec 12
Consensus estimates of losses per share improve by 31% Dec 12
Consensus estimates of losses per share improve by 13% Nov 28
Consensus EPS estimates fall by 27% Nov 09 Galapagos NV to Report First Half, 2024 Results on Aug 01, 2024
Third quarter 2023 earnings released: EPS: €0.39 (vs €0.33 in 3Q 2022) Nov 03
High number of new directors Oct 01
Galapagos NV Announces Board Changes Sep 21 Galapagos NV to Report Q4, 2023 Results on Mar 28, 2024
Galapagos NV Announces Start of Phase 2 Study with Selective Tyk2 Inhibitor, GLPG3667, in Patients with Active Systemic Lupus Erythematosus Aug 29
Consensus estimates of losses per share improve by 12% Aug 22
New major risk - Revenue and earnings growth Aug 06
Galapagos NV Revises Sales Guidance for the Full Year 2023 Aug 04
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 04
Lacklustre Performance Is Driving Galapagos NV's (AMS:GLPG) Low P/S Jul 18 Galapagos Appoints Thad Huston as Chief Financial Officer, Effective from July 1, 2023
Galapagos NV Announces Director Changes Jun 14
Galapagos to Showcase CAR-T Point-Of-Care Manufacturing and Initial Phase 1/2 CLL Data with CD19 CAR-T Candidate, GLPG5201, at the EHA 2023 Congress Jun 07
Consensus EPS estimates fall by 30% Jun 01
Consensus EPS estimates fall by 19% May 25
Consensus EPS estimates upgraded to €2.71 loss, revenue downgraded May 11
€41.78: That's What Analysts Think Galapagos NV (AMS:GLPG) Is Worth After Its Latest Results May 06
First quarter 2023 earnings released: EPS: €0.35 (vs €0.20 loss in 1Q 2022) May 05
Price target decreased by 8.1% to €41.78 Apr 20
Here's Why We're Not Too Worried About Galapagos' (AMS:GLPG) Cash Burn Situation Mar 29
Full year 2022 earnings: EPS and revenues miss analyst expectations Mar 27
Consensus EPS estimates upgraded to €1.17 loss, revenue downgraded Mar 02
Full year 2022 earnings released: €3.32 loss per share (vs €1.92 loss in FY 2021) Feb 24
Price target decreased by 13% to €47.62 Feb 09
Galapagos NV Announces Topline Results from Phase 3 DIVERSITY Trial of Filgotinib in Crohn’s Disease Feb 09
Consensus EPS estimates fall by 48% Jan 27
Galapagos NV Announces Changes in the Executive Committee Effective 1 January 2023 Dec 23
Galapagos and CellPoint Presented Encouraging Initial Data AtASH 2022 for GLPG5101, a CD19 CAR-T Candidate Manufactured At Point-Of-Care Dec 14
Consensus forecasts updated Dec 09
Price target decreased to €52.86 Dec 05
Consensus estimates of losses per share improve by 84% Nov 16
Galapagos Announces CHMP Adoption of PRAC’s Recommendation for Jyseleca® Following Extensive Safety Review of all JAK Inhibitors Nov 12
Galapagos NV to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022 Nov 10
Galapagos NV to Report Fiscal Year 2022 Final Results on Mar 23, 2023 Nov 08
Third quarter 2022 earnings released: EPS: €0.30 (vs €0.99 loss in 3Q 2021) Nov 05 Galapagos NV to Report Q1, 2023 Results on May 04, 2023
Galapagos Receives Positive CHMP Opinion for Jyseleca® European Label Update Based on Testicular Function Safety Data from MANTA/RAy Studies Oct 04 Galapagos NV announced that it has received €3.07625 million in funding Sep 29
Consensus EPS estimates have been downgraded. Aug 23
Consensus forecasts updated Aug 11
Galapagos NV Revises Revenue Guidance of Jyseleca for the Full Year 2022 Aug 10
Second quarter 2022 earnings released: €0.29 loss per share (vs €0.98 loss in 2Q 2021) Aug 05
Consensus forecasts updated Jul 25 Galapagos NV (ENXTAM:GLPG) entered into a definitive agreement to acquire Abound Bio, Inc. for $14 million. Galapagos NV announced that it expects to receive €1.459507 million in funding Jun 21
High number of new directors May 31
Consensus estimates of losses per share improve by 13% May 26
Consensus forecasts updated May 13 Shareholder Returns GLPG NL Biotechs NL Market 7D 1.0% 1.0% -1.7% 1Y -29.6% 11.4% 4.3%
See full shareholder returns
Return vs Market: GLPG underperformed the Dutch Market which returned 4.3% over the past year.
Price Volatility Is GLPG's price volatile compared to industry and market? GLPG volatility GLPG Average Weekly Movement 4.5% Biotechs Industry Average Movement 7.5% Market Average Movement 4.1% 10% most volatile stocks in NL Market 7.0% 10% least volatile stocks in NL Market 2.3%
Stable Share Price: GLPG has not had significant price volatility in the past 3 months compared to the Dutch market.
Volatility Over Time: GLPG's weekly volatility (5%) has been stable over the past year.
About the Company Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l.
Show more Galapagos NV Fundamentals Summary How do Galapagos's earnings and revenue compare to its market cap? GLPG fundamental statistics Market cap €1.69b Earnings (TTM ) -€60.61m Revenue (TTM ) €260.09m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) GLPG income statement (TTM ) Revenue €260.09m Cost of Revenue €331.48m Gross Profit -€71.38m Other Expenses -€10.77m Earnings -€60.61m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 12, 2025
Earnings per share (EPS) -0.92 Gross Margin -27.45% Net Profit Margin -23.30% Debt/Equity Ratio 0%
How did GLPG perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 00:36 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Galapagos NV is covered by 34 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution René Verhoef ABN AMRO Bank N.V. Emily Field Barclays Patrick Trucchio Berenberg
Show 31 more analysts 
